罗格列酮联合胰岛素治疗2型糖尿病临床疗效观察

目的探讨罗格列酮联合胰岛素治疗2型糖尿病的治疗效果。方法42例2型糖尿病患者随机分为：胰岛素组（Ins），n=21；罗格列酮联合胰岛素组（Ins＋Ros），n=21。Ins组采用诺和灵R于早、中、晚三餐前及诺和灵N睡前皮下注射治疗；Ins＋Ros组加用罗格列酮，4mg／d，并根据血糖水平调整用量4～8mg／d，治疗16周。两组患者于治疗前、治疗后测BMI、FPG、2hPG、HbAlc、FCP、TC、TG、LDL—C、HDL—C等指标，两组进行对比。结果Ins＋Ros组FPG、2hPG、HbAlc、TG、TC、LDL-C等和治疗前及Ins组治疗后相比均明显下降（P〈0．05），BMI、FCP等和治疗前及组间对比均无统计学差异（P〉0．05）。结论罗格列酮在治疗2型糖尿病过程中，可以明显改善胰岛素抵抗，降低血糖、血脂，在临床中联合使用胰岛素进行治疗，可以更好的促进2型糖尿病患者的康复。

Clinic effect study of treatment on T2-DM utilizing rosiglitazone associated with insulin

Objective To discover clinic effect on T2-DM utilizing rosiglitazone associated with insulin. Methods 42 T2-DM patients were divided into two groups：Ins group,n=21 ;Ins＋Ros group, n=21. In Ins group,Novolin R was hypodemic injected before three meals and Novolin N before retiring; In Ins＋ Ros group, rosiglitazone was added with 4mg/d, justified from 4- 8mg/d. Time of therapy was 16 weeks. Index of BMI, FPG, 2hPG were measured pro-therapy and post-therapy. Results In Ins-kRos group,index of FPG, 2hPG, HbAlc, TG, TC, LDL-C descended obviusly compared with pro-therapy and Ins group post-therapy （P 〈 0.05）, Index of BMI, FCP changed slightly （P 〉 0. 05）. Conclusions Rosiglitazone can heal insulin resistance obviously and lower blood sugar, blood fat, and it can improve T2-DM patients treatment.